{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:18:11Z","timestamp":1783487891627,"version":"3.55.0"},"reference-count":0,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,10,29]],"date-time":"2003-10-29T00:00:00Z","timestamp":1067385600000},"content-version":"vor","delay-in-days":2433,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1997,3]]},"abstract":"<jats:p>BACKGROUND AND OBJECTIVES\u2003Adequate assessment of patients on glucocorticoid replacement therapy is of great importance to avoid the consequences of under or over treatment, but no simple test is available for this. The aims of this study were (1) to assess adequacy of glucocorticoid replacement in hypoadrenal patients, (2) to correlate serum cortisol levels (cortisol day curve) with 24\u2010hour urine free cortisol excretion and (3) to assess the impact of glucocorticoid dose optimization on markers of bone formation and bone resorption.<\/jats:p><jats:p>DESIGN\u2003Cross\u2010sectional study of current replacement therapy and a prospective study of the effect of dose alteration on bone turnover markers.<\/jats:p><jats:p>PATIENTS\u2003Thirty\u2010two consecutive patients on replacement glucocorticoid therapy (12 Addison\u2019s disease, 20 hypopituitarism) from a University teaching hospital out\u2010patient department.<\/jats:p><jats:p>MEASUREMENTS\u2003Serum and urinary cortisol, osteocalcin, N\u2010telopeptide of type I collagen (NTX) and bone mineral density.<\/jats:p><jats:p>RESULTS\u200328\/32 (88%) patients required a change of therapy; 24\/32 (75%) a total reduction in dose, 18\/32 (56%) a change in replacement therapy regimen or drug and 14\/32 (44%) both changes. The mean daily dose of hydrocortisone was reduced from 29.5\u2003\u00b1\u20031.2 to 20.8\u2003\u00b1\u20031.0 mg. A significant correlation was found between peak cortisol and 24\u2010hour urine free cortisol\/creatinine (Spearman correlation <jats:italic>r<\/jats:italic>\u2003=\u20030.60, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001; <jats:italic>n<\/jats:italic>\u2003=\u200351). Following hydrocortisone dose reduction, median osteocalcin increased from 16.7 \u03bcg\/l (range 8.2\u201365.7) to 19.9\u2003\u03bcg\/l (8.2\u201356.3); <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01, with no change in the NTX\/creatinine ratio.<\/jats:p><jats:p>CONCLUSIONS\u2003A high proportion of patients on conventional corticosteroid replacement therapy are over treated or on inappropriate replacement regimens. To reduce the long term risk of osteoporosis, corticosteroid replacement therapy should be individually assessed and over replacement avoided.<\/jats:p>","DOI":"10.1046\/j.1365-2265.1997.780907.x","type":"journal-article","created":{"date-parts":[[2003,11,7]],"date-time":"2003-11-07T20:05:51Z","timestamp":1068235551000},"page":"255-261","source":"Crossref","is-referenced-by-count":164,"title":["Glucocorticoid replacement therapy: are patients over treated and does it matter?"],"prefix":"10.1111","volume":"46","author":[{"given":"Steven R.","family":"Peacey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun\u2010Yuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Weetman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,29]]},"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1997.780907.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1997.780907.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1997.780907.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T10:41:11Z","timestamp":1698403271000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1997.780907.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,3]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,3]]}},"alternative-id":["10.1046\/j.1365-2265.1997.780907.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1997.780907.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,3]]}}}